Abstract | BACKGROUND: METHODS: All patients taking a glyburide/metformin preparation at the Carl T. Hayden VAMC were identified from pharmacy records. Patients with documented hemoglobin A values within 31 weeks prior and between 3 and 33 weeks after initiation of therapy (92 subjects) were examined. RESULTS:
Glyburide/metformin combination therapy reduced hemoglobin A levels from 0.087 to 0.083 (P < 0.06). Significant reductions were seen in those patients with initial levels higher than 0.08 (0.094 to 0.087; P < 0.01). No significant reductions were seen in those patients with initial levels lower than 0.08. CONCLUSIONS:
|
Authors | Syed U Bokhari, Usha M Gopal, William C Duckworth |
Journal | The American journal of the medical sciences
(Am J Med Sci)
Vol. 325
Issue 2
Pg. 66-9
(Feb 2003)
ISSN: 0002-9629 [Print] United States |
PMID | 12589230
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)
|
Chemical References |
- Blood Glucose
- Drug Combinations
- Glucovance
- Hypoglycemic Agents
- Insulin
- Hemoglobin A
- Metformin
- Glyburide
|
Topics |
- Blood Glucose
(metabolism)
- Diabetes Mellitus, Type 2
(drug therapy)
- Drug Combinations
- Glyburide
(therapeutic use)
- Hemoglobin A
(metabolism)
- Humans
- Hypoglycemic Agents
(therapeutic use)
- Insulin
(metabolism)
- Insulin Resistance
(physiology)
- Metformin
(therapeutic use)
|